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In vivo active organometallic-containing
antimycotic agents†
Riccardo Rubbiani,*a Tobias Weil, *b Noemi Tocci, b Luciano Mastrobuoni,a
Severin Jeger,a Marco Moretto, c James Ng, d Yan Lin, d Jeannine Hess, a
Stefano Ferrari, e Andres Kaech,f Luke Young, g John Spencer, g
Anthony L. Moore, h Kevin Cariou, *d Giorgia Renga, i Marilena Pariano, i
Luigina Romani i and Gilles Gasser *d
Fungal infections represent a global problem, notably for immunocompromised patients in hospital,
COVID-19 patient wards and care home settings, and the ever-increasing emergence of multidrug
resistant fungal strains is a sword of Damocles hanging over many healthcare systems. Azoles represent
the mainstay of antifungal drugs, and their mode of action involves the binding mode of these
molecules to the fungal lanosterol 14a-demethylase target enzyme. In this study, we have prepared and
characterized four novel organometallic derivatives of the frontline antifungal drug fluconazole (1a–4a).
Very importantly, enzyme inhibition and chemogenomic profiling demonstrated that lanosterol
14a-demethylase, as for fluconazole, was the main target of the most active compound of the series,
(N-(ferrocenylmethyl)-2-(2,4-difluorophenyl)-2-hydroxy-N-methyl-3-(1H-1,2,4-triazol-1-yl)propan-1-aminium
chloride, 2a). Transmission electron microscopy (TEM) studies suggested that 2a induced a loss in cell wall
integrity as well as intracellular features ascribable to late apoptosis or necrosis. The impressive activity of 2a
was further confirmed on clinical isolates, where antimycotic potency up to 400 times higher than
fluconazole was observed. Also, 2a showed activity towards azole-resistant strains. This finding is very
interesting since the primary target of 2a is the same as that of fluconazole, emphasizing the role played
by the organometallic moiety. In vivo experiments in a mice model of Candida infections revealed that
2a reduced the fungal growth and dissemination but also ameliorated immunopathology, a finding
suggesting that 2a is active in vivo with added activity on the host innate immune response.
Introduction
Mycoses are one of the most common opportunistic infections
worldwide, affecting poor as well as industrialized countries.
Skin infections (e.g. athlete’s foot), for example, affect 20–25%
of the world’s population and systemic opportunistic infections
are the 4th common cause of bloodstream infections with a
lifetime incidence of about 75% (e.g. in the case of Candidiasis).1–6
Even if such extensive morbidity does not lead to a high mortality
rate, local opportunistic infections together with invasive fungal
infections (IFI) have a deep impact on the entire health system
because they suppress the immune system and thus, increase the
risk to develop other/additional pathologies, which can be fatal to
immunosuppressed people.7–16 Although potent drugs (e.g.
clotrimazole) are applied in antifungal therapy, the infection
rate is worryingly increasing every year. Moreover, incidences of
resistance to conventional antimycotics are steadily increasing,
especially for long term therapies that last from several weeks to
months.17 Main mechanisms necessary for antifungal resis-
tance are drug target mutations (e.g. mutations of CYP51A1),
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upregulation of efflux channels (e.g. major facilitator super-family
(MFS) and ATP-binding cassette (ABC channels)), aneuploidy and
loss of heterozygosity (LOH) and modulation of the stress response
(e.g. translational signal pathways, RNA dependent response).18–21
Surprisingly, despite a pressing need for novel antifungal agent
research and drug development, there is an apparent downturn
in such activities.22 However, the recent COVID-19 pandemic
has witnessed numerous examples of COVID-19 and C. auris
co-infections, adding further pressure to healthcare systems.23
Cell wall targeting is at the basis of modern antifungal therapy
since it is absent in mammalian cells allowing for selectivity. A
selective destabilization or inhibition of cell wall biosynthesis
leads to metabolic onset, growth arrest and culminates in fungal
death. For decades, Amphotericin B deoxycholate (AmB) has been
the only available treatment for invasive fungal infections (IFIs).24
However, during the last ten years, the growing number of IFI
incidences has stimulated the introduction of four new classes of
antifungal agents, namely polyene-based compounds, azoles,
allylamines and echinocandins.25–28 Inhibition of cell wall bio-
synthesis is associated with an accumulation of sterol toxic
precursors, cell wall destabilization and cellular stress. During
the second half of the 20th century, antifungal research mainly
focused on an intensive derivatization of accepted compounds
(e.g. from ketoconazole to fluconazole of from AmB to Nystatin
and AmB liposomes).19–21 Despite these efforts, to date, only
seven compounds are included in the World Health Organization
Essential Medicine list (WHO-EM, data of October 2013).1–6
Moreover, the benchmark drugs were all discovered almost 20
or more years ago and accounts of ineffective therapies have been
reported for several of these agents especially towards Candida
albicans (C. albicans) and Aspergillus terreus.1–6 For this reason,
and encouraged by the spectacular results obtained with metal
complexes (e.g. salvarsan, cisplatin, auranofin, ferroquine, ferro-
cifen, etc.) in other medicinal fields,29–38 some groups have
decided to assess the potential of such compounds to fight fungal
infections.39,40 Despite such a wealth of promising examples of
metal-based drugs, there is a paucity of examples of such
compounds applied in the field of antifungal therapy. Here, just
sporadic reports confirmed the effectiveness of different transi-
tion metal complexes (e.g. Co(II), Ni(II), Cu(II), Pd(II) complexes)
bearing a variety of ligands (e.g. azole moieties, thiosemicarbazones,
carboxamides, indoles) against several fungal strains or some
organometallic moieties bound to active antifungal agents.41–53
However, all these studies generally provided only MIC50 values
without any further biological investigation such as target engage-
ment and toxicity. Willing to grasp this opportunity, we embarked
on a research program to unveil potent complexes against fungal
infections with an emphasis on addressing cellular targets and
mode of action. Herein, we present the identification of a
metallocene-based lead compound against such infections.
Results and discussion
Synthesis and characterization
The two most common antifungal drugs inscribed in the List of
Essential Medicine of the WHO and commercially available,
namely clotrimazole and fluconazole (Fig. 1), belong to the azole
class. The molecular target for both those azoles was found to be
the enzyme lanosterol-14a-demethylase.47 Of utmost interest,
mammalian cells use cholesterol instead of ergosterol. This
important difference secures high selectivity for the reported
antimycotics.54 Recently, the broad therapeutic applications of
clotrimazole as well as fluconazole against skin, genital and
invasive fungal infections have generated comparison of primary
or cross resistance, especially for Candidiasis.55,56 Motivated by
the promising results obtained from the ferrocenyl derivatization
of organic drugs such as tamoxifen and chloroquine to give
ferrocifen and ferroquine, respectively, we envisaged applying
the same concept to fight fungal infections.32,49,57–59 Fluconazole
has been chosen as the parent drug because of its broad
spectrum applications (e.g. systemic and topic administration,
active against a large number of mycoses). The drug design took
into consideration the mode of action of fluconazole and its
interaction with the active site of the target enzyme. Computing
binding geometry data showed how fluconazole activity is exerted
by the interaction of the triazole moiety (i.e. the nitrogen atom
highlighted in blue in Fig. 1) with the haem group present in the
active site of the target enzyme (i.e. the iron atom).60 This
interaction is also favoured by the presence of the difluorophenyl
group that is located in the enzyme active site, in (close) proximity
to the hydrophobic binding cleft and interacts with it via p–p
Fig. 1 Chemical structures of the main antifungal therapeutics present on the market (clotrimazole and fluconazole) and our fluconazenes 1–4,
highlighted in blue are the nitrogen responsible for the binding with the haem group.
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stacking.60 On the contrary, the second triazole moiety is involved
in non-bonding interactions with several prosthetic groups
present in the enzyme cavity. Interesting work by Sheng and
co-workers, involving protein docking studies, demonstrated that
organic modification with different functional groups at the C3
atom of fluconazole resulted in an increased activity in relation to
the parent drug. This was supported by MIC80 values. Therefore,
in the present case, we aimed at derivatizing the fluconazole core
on the triazole not involved in the binding pocket interaction,
replacing it with a ferrocenyl moiety. Ferrocenyl derivatization is
proposed to play an important role for the overall biodistribution
and uptake (e.g. increasing the lipophilicity of the parent drug) as
well as in potentially allowing for an additional redox-induced
mode of action as observed for ferrocifen and ferroquine.32,57,58,61
Finally, different alkyl substituents were inserted at the bridging
nitrogen in order to garner Structure–Activity Relationship (SAR)
information. The target ferrocenyl compounds of this study,
namely 1a–4a can be seen in Fig. 1. Herein, we name them
fluconazenes.
The synthesis of the new fluconazenes 1–4 can be visualized
in Scheme 1. In the envisioned retrosynthesis (Scheme 1A), the
target compounds would be obtained from the addition of a
ferrocenylamine (5) on the epoxide 6, easily accessible from
1,2,4-triazolo-ketone 7, which is commercially available, by a
Corey–Chaykovski epoxidation. The ferrocenylmethanamines
(5a–d) were prepared from ferrocene carboxaldehyde (8) in
two steps, following adapted procedures by Tice et al. and
Baramee et al.62,63 Reaction of the aldehyde (8) with hydroxyla-
mine hydrochloride under basic conditions yielded the oxime
(9a). The imines (9b–d) were obtained by stirring 8 in the
presence of a solution of the corresponding alkyl amines. The
intermediates (9a–d) were reduced to amines (5a–d) with
LiAlH4 and NaBH4, respectively. Spectroscopic data of 5a–d
matched those reported in the literature (Scheme 1B).62–64 Epoxide
6 was obtained in 76% yield by treating ketone 5 with a solution of
trimethylsulfoxonium iodide ylide (Scheme 1C).60,65 The subse-
quent epoxide ring opening of 6 with the primary and secondary
ferrocenemethanamines (5a–d) yielded compounds 1–4.64,65 The
derivative carrying the methylamine linker (2) was obtained in
noticeably higher yield (46%) than the other derivatives (1, 30%; 3,
31%; 4, 20%). This can be attributed to the donating inductive
effect of the alkyl groups on the N atom, which increases the
nucleophilic strength of 9b–d. In contrast, the growing steric
hindrance of the ethyl and isopropyl group can explain the
decreasing yield within the series of tertiary amines (2 4 3 4 4).
While fluconazole is achiral, with two identical 1,2,4-triazolyl-
methyl side chains attached to the C2 carbon, our derivatives 1–4
are chiral. However, according to molecular docking experiments
of chiral fluconazole derivatives by Sheng et al., both R and S
isomers, can interact with the active site of the C. albicans CYP51
through a similar binding mode,66 thus avoiding the need for a
chiral separation, or an asymmetric synthesis of a specific
enantiomer.67 The derivatives 1–4 were converted to the corres-
ponding hydrochloride salts by treatment with HCl in acetone,
following an adapted procedure of Bader et al. (Scheme 1D).68
Overall, the new complexes 1a–4a were all characterized via 1H,
13C, 19F NMR, MS, IR and their purity was confirmed via elemental
analysis and UPLC-MS (see Fig. S2–S29 in ESI†).
Stability
As potential drug candidates, the hydrochloride salts 1a–4a
need to be stable in DMSO, which is the administering medium
for in vitro and in vivo studies, as well as in the biological
medium, namely water. It was previously demonstrated that this
can be problematic for metal-based drugs.69–71 The stability of
1a–4a was assayed by dissolving the salts in deuterated solvents,
namely neat DMSO-d6 and neat D2O, and by monitoring the
samples using 1H NMR spectroscopy over a period of 48 hours
(see ESI† for details). It is worth mentioning that 1a and 4a are
only sparingly soluble in D2O. Generally, all four hydrochloride
salts were stable for up to 24 hours and only little decomposition
was observed for 2a and 4a in water after 48 h.
In vitro biological screening
To assess the antifungal activity of the new drug candidates, we
employed a well-plate based assay recently developed in our
group.39 The first antimycotic investigation was performed on
the solid and largely used model system S. cerevisiae. Therefore,
S. cerevisiae was cultured and diluted to reach the beginning of
the growing phase just before treatment. YPD agar terrain at
increasing concentrations of the target complexes were poured
on a 6 or 12-wells plate and the S. cerevisiae culture were then
spotted on them and incubated for 24 h at 30 1C. Interestingly, all
compounds displayed an improved antifungal activity compared
to the parent drug (e.g. see Fig. 2). Small alkyl group-substituted
tertiary amines (complexes 2a and 3a) as linkers, showed an
improved profile, between 9–17-fold, compared with secondary
amines (see Table 1).
To further evaluate the potential of the compounds, we
investigated their host toxicity, in vitro mycotoxicity and cellular
uptake. An effective inhibitor would need a good therapeutic
window, with low host toxicity versus effective nM fungal toxicity
The first investigation on the new antimycotic drug candidates
involved their possible influence on host cells and their efficiency
towards a common fungal model. We investigated the anti-
proliferative effect of 1a–4a in vitro on human retinal pigment
epithelial cell (RPE-1-hTert) and human fibroblast (MRC-5). As
expected, fluconazole displayed only moderate effects on cell
viability. All complexes displayed IC50 values in the mid-high
micromolar range, following the order of potency: isopropyl (4a) 4
ethyl (3a) 4 methyl (2a) 4 H (1a) (see Table 1). This suggests that a
decrease in the size of the N-substituent (i.e., a decrease in
lipophilicity) correlates with a decrease in host toxicity. Overall,
while the organometallic compounds are slightly more toxic than
fluconazole, the toxicity remains relatively moderate, especially
taking into account that the toxicity towards yeast is much
higher (see below).
In order to investigate the pharmaco-dynamic profile of the
target antimycotic drug candidates, a series of uptake studies in
S. cerevisiae were performed. The uptake measurements were
performed via ICP-MS by detecting the free iron content in the
culture medium and normalizing it against the colony density
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at different incubation times (1 h, 6 h and 18 h). The results were
then compared with the survival rate measured via OD (see Fig. 3).
The uptake of the target complexes followed the order 4a { 1a o
3a o 2a and fits very well with their time-dependent mycotoxicity.
This suggests that complexes with sterically-hindered groups like
an isopropyl or the less lipophilic complex 1a showed a lower
efficacy than ones with short chain alkyl groups (2a, 3a).
In order to assess the possible increase in reactive oxygen
species (ROS) level induced by 1a–4a, possibly due to the
presence of the ferrocenyl moiety, we performed a series of
in vitro experiment to measure the ROS level upon treatment on
S. cerevisiae. Briefly, S. cerevisiae was cultured in YPD medium
overnight before treatment. After that, the fungal concentration
was measured and normalized and the cultures were treated
Scheme 1 (A) Retrosynthetic analysis; (B) preparation of the primary (7a) and secondary (7b–d) ferrocenylmethanamines via the oxime (9a) and imine
(9b–d) intermediates. Overall yields, comprising both steps: 7a, 71%; 7b, 56%; 7c, 60%; 7d, 81%; (C) synthesis of the organometallic fluconazole
derivatives (1–4), which feature an amine-linked ferrocene moiety; (D) synthesis of the hydrochloride salts of 1–4 (1a–4a).
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with YPD containing 5 mM of the different drug candidates at
different time frames (1 h, 6 h and 18 h). After incubation, the
colonies were washed, fresh medium containing H2DCF
was added and the fluorescence of the hydrolyzed DCF was
measured (see Fig. S1, ESI†). While the parent drug fluconazole
displayed weak action at early stages, which increased with
incubation time, the new drug candidates showed a higher ROS
levels at an early stage. However, although the complexes
proved to induce an increase of ROS levels, the relative ROS
induction still remains moderate and it is probable that ROS
production is not responsible for fungi death.
Morphology studies
The activity of 2a at the biochemical level is also mirrored by
morphologic features at the ultra-structural level. The morphologic
effect on S. cerevisiae upon treatment with the target complex
could be conveniently monitored by transmission electron
microscopy (TEM). As can be seen in Fig. 4, the resulting images
(selection of a large pool) suggested that 2a induces a loss in
wall integrity as well as intracellular features ascribable to late
apoptosis or necrosis.
In vitro antifungal screening on clinical isolates
Motivated by the promising results obtained for the in vitro
antifungal activities against the non-pathogenic model system
S. cerevisiae, we performed further screening on clinical isolates.
We again chose complex 2a since it displayed the best mycotoxicity
and, on the other side, showed low cytotoxicity against human
cells. We tested this antifungal drug candidate towards C. albicans
and non albicans strains, including fluconazole-resistant (MIC50 4
100 mM) and other mycotoxin-producing and pathogenic fungi,
such as Penicillum paneum, Aspergillus glaucus and Trichosporon
asahi (see Table 2). Of utmost interest, the new antifungal drug
candidate displayed a very strong activity towards almost all
investigated strains (only in the case of A. glaucus, C. parapsilosis,
and C. albicans MFB005 and SC5314 was the MIC50 not in the
nanomolar range). Moreover, the antimycotic potency of the
complex did overcome the values of the parent drug up to a factor
of 400-fold (e.g. P. paneum) and also showed activity towards azole
resistant strains.
Fluconazole is a fungistatic drug and growth curve analysis per-
formed on the C. albicans reference strain SC5314, a frequently used
wild-type control, indicate a fungistatic effect of compound 2a at
MIC50 concentration for this specific strain (1.98 mM, Fig. S2, ESI†).
AOX enzyme inhibition
In order to further define the inhibitory capabilities of the
compounds, they were also tested in the mitochondrial complex
II and III pathway (succinate quinol reductase pathway (SQR)), two
common targets for fungicidal treatment.72,73 As can be seen in
Fig. 5, compound 1a demonstrated no inhibitory activity towards
either complex, confirming that the antifungal properties of these
compounds are not due to off-target effects within mitochondrial
respiration. However, while the other analogues demonstrate
slightly improved inhibitory properties against the pathway when
compared to 1a, it is unlikely to be the source of fungicidal activity.
Fig. 2 Depicted example of a colony formation inhibition experiment; (A)
S. cerevisiae treated with fluconazole; (B) S. cerevisiae treated with 1a; (C)
S. cerevisiae treated with 2a; (D) S. cerevisiae treated with 3a; (E) S.
cerevisiae treated with 4a. S. cerevisiae has been treated with increasing
concentrations of the target drug candidates ranging from 2.5 up 200 mM
(higher concentration not depicted) and incubated at 30 1C for 24 h. The
experiments with the drug candidates and with negative control of
untreated colony have been performed in triplicate.
Table 1 Host toxicity of the new fluconacenes against RPE and MRC-5
human cell lines (expressed as IC50) and inhibition of colony formation in S.
cerevisiae treated with increasing concentrations of the 1a–4a for 24 h at
30 1C; fluconazole was used as parent drug for comparative purposes;
values are expressed in mM. The activity of compounds 1a–4a on S.
cerevisiae was evaluated via a newly established colony formation
assay39
Compound MRC5 RPE S. cerevisiae
Fluconazole 4100 4100 51.0  3.7
1a 94.6  2.4 4100 13.2  3.0
2a 32.2  0.1 74.7  5.2 3.02  2.18
3a 70.4  17.9 51.2  0.1 5.86  0.41
4a 59.4  2.8 48.4  2.9 9.62  0.56
Fig. 3 Uptake studies compared to the colony survival rate measured in
OD. The experiment has been performed on the medium of incubation
and corrected with OD in order to take into account of the possible
biological material loss due to toxicity of the compounds and which would
lead to decrease in uptake. Negative controls of the untreated and of the
medium alone have been also performed.
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The compounds were also tested against alternative oxidases
(AOX) from both C. albicans and C. auris. The proteins were
expressed in a recombinant E. coli system to allow for more
accurate data acquisition due to their low expression levels
proving problematic from a detection standpoint. Again,
compound 1a demonstrated minimal inhibitory activity towards
the AOX’s, however compounds 3a and 4a showed moderate
activity against both AOX’s, comparable to values typically seen
with non-competitive AOX inhibitors such as salicylhydroxamic
acid (SHAM).74 The parent compound, fluconazole, displayed
no inhibition towards either pathway up to a concentration
of 100 mM.
Cytochrome P450 enzyme inhibition
Based on the very promising data obtained with complex 2a,
further biological experiments were performed on this complex
to understand further its mechanism of action. Enzyme inhibition
studies were performed on different cytochrome P450 enzymes by
the service provider Cyprotex GmbH. The new fluconacene 2a
displayed an extremely strong inhibition profile throughout all the
series of enzymes, with a larger efficacy in comparison with the
parent drug fluconazole, between 4 and 150 fold (see Table 3)
suggesting that, if this series of molecule are optimised towards
clinical use, like fluconazole,75 potential drug–drug interactions
will need to be taken into account.
Fig. 4 Ultra-structural studies of untreated S. cerevisiae, treated with 2a or with fluconazole tested at 5 mM and 30 1C incubation temperature. The
pictures showed starting with a 6 h incubation formation of vesicles, ascribable as apoptotic bodies and loss of membrane integrity. After longer
incubation times a shrinking effect as well as nuclear blebbing could be also noted.
Table 2 MIC50 values on a pool of fungal pathogens treated with 2a
Strains MIC50 2a (mM) MIC50 fluconazole (mM)
C. albicans SC5314 41 0.82
C. albicans MFB005 FS3 41 0.41
C. albicans YMS 102-2 1.00 4100
C. albicans YMS 102-6 0.06 0.82
C. glabrata MFB005 FS4 0.06 0.41
C. glabrata RTT 199_3 1.00 4100
C. parapsilosis MFB005 FS5 0.50 0.41
C. parapsilosis MFB070 N1 41 4100
C. tropicalis RTT35-1 0.69 4100
C. tropicalis RTT35-3 0.50 4100
P. paneum MFB042 N1 0.25 4100
A. glaucus MFB027 N1 41 0.82
T. asahii MFB034 N1 0.13 1.63
Fig. 5 pIC50 values (log IC50) for all compounds against the mitochon-
drial complex II and III pathway (SQR) from rat liver mitochondria, and
rAOX’s from C. albicans and C. auris. Control denotes control compounds
for each specific pathway, with antimycin A for SQR and ascofuranone for
the AOX pathways. Data was collected in a 96-well plate format, following
cytochrome c reduction (DA550) for the SQR pathway, and NADH oxidation
(DA340) for the AOX pathway. All data are a mean average of 3 biological
replicates SEM.
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Chemogenomic studies
In order to investigate the mechanism of action of the new organo-
metallic complex 2a, chemogenomic assays were performed. The
strength of the genome-wide chemogenomic screen is reflected in
the clear identification of ERG11, encoding lanosterol 14-alpha-
demethylase, as the main target of the drug (see Fig. 6 and
Table S1, ESI†). ERG11 is a key enzyme of the ergosterol biosynthesis
pathway and the primary target of azole antifungals to which the
tested compound 2a belongs.
Azoles are known to induce ERG11 gene expression,76 which
also holds true for compound 2a yet to a lower extent than
fluconazole as revealed by a screen in both susceptible
C. albicans strains (Fig. S3A, ESI†) and in the highly fluconazole
resistant strain YMS102-2 (Fig. S3B, ESI†). The latter strain
showed a high expression of ERG11 when grown in the absence
of drug and ERG11 gene expression was significantly (FC = 1.69;
P = 0.000086) increased upon fluconazole exposure, while
decreased (FC = 1.81; P = 0.000193) when grown in the
presence of compound 2a (Fig. S3B, ESI†). Hence, the improved
antifungal activity of compound 2a for the strain YMS102-2
might be partially explained by the significant reduction of
ERG11 gene expression, because overexpression of ERG11 is
known as an azole resistance mechanism in Candida.16,77
Hence, future work should be directed to study if compound
2a is able to reduce ERG11 gene expression also in other ERG11
overexpressing Candida isolates in a similar way.
Our chemogenomic assay identified five other heterozygous
deletion strains that in previous chemogenomic screens have
been shown to be extremely sensitive to azole antifungals; these
are SET6, PDR5, PDR16, MED4 and CDC39. The latter two are
essential nuclear genes involved in the regulation of transcription.
CDC39 acts as a component of the CCR4-NOT core complex78 and
MED4 encodes a subunit of the RNA polymerase II mediator
complex. In Saccharomyces cerevisiae and C. glabrata the mediator
complex is a coactivator of the multiple drug resistance regulator
PDR1 that controls the activation of PDR5 and PDR16.79–81 Simi-
larly, also in C. albicans the mediator activator complex is recruited
to the CDR1 promotor,80 which is the C. albicans ortholog of PDR5.
PDR5 is a multidrug ABC efflux pump that confers resistance to
several chemicals including azoles and it mediates transmem-
brane transport of steorids.82 PDR16 (ortholog of the C. albicans
PDR17) is a phosphatidylinositol transfer protein involved in sterol
biosynthetic process and in resistance to azole drugs.83 Notably,
the phosphatidylinositol signal transduction pathway that controls
amongst others cell membrane and cell wall remodelling as well as
downstream targets such as DNA repair, was recently suggested to
Table 3 Enzyme Inhibition studies of different cytochrome P450 enzyme by the compound 2a and its parent drug (IC50 in mM). Standard deviation
shown in upper script
Compound CYP2C9 CYP2C8 CYP2C19 CYP3A4 CYP1A CYP2D6
Fluconazole 13.9  1.63 97.2  27.9 3.02  0.34 25.8  2.45 4100 4100
2a 3.33  0.71 0.64  0.09 o0.4 0.4  0.06 10.4  0.41 2.71  0.12
Fig. 6 Chemogenomic screen. To identify potential drug targets the pool of tagged 5936 S. cerevisiae heterozygous deletion mutants was grown
competitively for 20 generations in the presence and absence of compound 2a. Strain fitness was determined via high-throughput barcode sequencing
and normalization to the untreated control. log 2 ratio (control intensity/treatment intensity) was calculated and plotted as a function of gene. The
genome-wide readout of heterozygous mutants highly sensitive to compound 2a included the known target of azoles, ERG11 and novel targets such as
the RAN GTPase GSP1 (red dots: log FC 4 1.5 and P value 40.01).
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play an important role in phenotypic antifungal drug resistance
related to protein synthesis.18 Indeed many of the identified deletion
strains that are highly sensitive to compound 2a were heterozygous
for genes involved in protein synthesis (e.g. ARC1, RPS5, MED4,
CDC39, SNF6, CCT5, GSP1) (Fig. 4 and Table S1, ESI†).
Furthermore, compound 2a targets nuclear genes that are
not only essential for RNA transcription, processing and
transport (GSP1, MED4, CDC39) but also essential for DNA
replication (SLD5), and these together with gene targets functioning
in the correct folding of actin and tubulin (CCT5) (Fig. 6) point to a
possible interaction of compound 2a with cell division.
Taken together, the genome-wide profiling of the in vivo
cellular response to compound 2a identified candidate protein
targets (Fig. 6 and Table S1, ESI†), which hint to a mechanism
Fig. 7 Effect of the compound 2a on C. albicans (SC-5314) systemic infection. C57BL/6 mice were infected via systemic route with 1  106 C. albicans
yeasts. Fluconazole and compound 2a were administered intragastrically daily, beginning the day of the infection until mice sacrifice (4 days after the
infection). Control mice received the diluent alone. (A) Fungal growth. (B) Histological scores and (C and D) analysis (10 magnification and 40 in the
inset) of the kidneys and colon of infected and treated mice. (E) Levels of cytokines in kidney homogenates. For histological scores of kidneys, score 0 =
no inflammation, score 1 r 3 foci of inflammation, score 2 = 4 to 6 foci of inflammation, score 3 Z 6 foci of inflammation, but less than 25% of kidney
affected, score 4 Z 25% of kidney affected. For histological scores of colon, the total histological score was obtained by summing the four histological
components scores: ‘inflammation extent’, ‘damage in crypt architecture’, ‘hyperemia/edema’, ‘grade of accumulation with inflammatory cells’. Data are
expressed as mean  SD. *P o 0.05, **P o 0.01, ***P o 0.005, treated vs. untreated C57BL/6 mice (n = 7 mice per group, representative of three
experiments). Naı̈ve, uninfected mice. None, untreated mice.
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of drug action that goes beyond the main targets of azole
antifungals, which might explain its elevated activity towards
azole resistant strains (Table 1).
In vivo studies
Motivated by these promising results, we decided to perform
in vivo experiments in a mice model of Candida infection. As
positive control, fluconazole was used. It significantly improved
pathology and cured mice from the infection, as judged by the
decreased fungal growth in the kidney and dissemination to
the liver (see Fig. 7A), reduction of the inflammatory pathology
in the kidney and colon (see Fig. 7B–D) and downregulation of
pro-inflammatory cytokine (IL-1b and TNF-a) levels (Fig. 7D).
Similar results were obtained with compound 2a that proved to
be effective in reducing fungal growth and dissemination (see
Fig. 7A) as well as tissue inflammatory pathology (see Fig. 6B for
histological scores) at a dose as low as 1 mg kg1 (Fig. 7C and D). Of
great interest, at variance with fluconazole, compound 2a also
promoted a vigorous pro-inflammatory cytokine response promptly
controlled by the associated high levels IL-10 (Fig. 7E). These
findings indicate that compound 2a is active in vivo and that its
activity may encompasse an action on innate immune response,
consistent with the well known synergistic activity of azoles, includ-
ing fluconazole, with antifungal effector activities, such as phago-
cytosis, radicals production and Toll-like receptors activation.84
Conclusion
Four novel ferrocene-based derivatives (1a–4a) of the frontline
antifungal drug fluconazole have been synthesized and char-
acterized. All four organometallic derivatives were tested for
antifungal activity against the model system S. cerevisiae and
showed an impressively improved activity compared to fluco-
nazole. Importantly, this activity was confirmed on a panel of
clinical isolates with the best candidate of this study (complex 2a).
An improvement of the minimum inhibitory concentration of up
to 400 times compared to fluconazole was observed and activity
against azole-resistant strains was clearly demonstrated for 2a.
During in vivo experiments in mice model of Candida infections,
compound 2a was found to diminish the growth of the fungus and
to greatly improve the inflammatory pathology in the kidney and
colon. Overall, this study further demonstrates the potential of
organometallic compounds in medicine. By merely inserting a
ferrocenyl moiety in a well-known drug, namely fluconazole,
resistance can be overcome, although the main target of the
novel antimycotic agent is the same as that of the organic
drug (lanosterol 14a-demethylase), as demonstrated by chemo-
genomic profiling. The ferrocenyl insertion allows for an
additional mode of action.
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N. Doucet, E. Déziel and A. Castonguay, ChemBioChem,
2020, 21, 3112–3119, and references therein.
52 J. A. d. Azevedo-França, R. Granado, S. T. de Macedo Silva,
G. d. Santos-Silva, S. Scapin, L. P. Borba-Santos, S. Rozental,
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